五星体育

五星体育

Pioneering For Patients

We are 五星体育

We are a biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation for more years of life and quality of life.

Our Intent to Separate into Two Publicly Traded Entities

On January 8, we announced a planned separation into two entities: 五星体育, which would continue to advance its global cell therapy leadership in addressing high unmet medical needs in oncology, and a newly to be formed company (鈥淪pinCo鈥�), which would focus on building a pipeline of innovative medicines through transformational transactions.

Read moreOur pipeline

Our Technology Platforms

Small Molecules

We are seeking partners to take over our small molecules鈥� assets, including the TYK2 inhibitor, GLPG3667, currently in Phase 2 for systemic lupus erythematosus, dermatomyositis, and other potential auto-immune indications.

Learn more

Our Technology Platforms

Cell Therapy

  • Scalable, decentralized, fast: stem-like, early memory cells near patients in median 7 days vein-to-vein
  • High-yielding discovery engine: multi-targeting, next-generation cell therapies
  • Diversify and grow: through partnerships and M&A
Discover more

LATEST PRESS RELEASES

More

STORIES OF PURPOSE

Pioneering for Patients, with Patients!

Patients and Carers

At 五星体育, we put patients鈥� care and well-being first and foremost.

Our goal is to improve patients鈥� quality of life through life-changing science and innovation.

Discover our commitment to pioneering for patients, with patients!

Discover our commitment